Literature DB >> 7947105

Neurological illness following treatment with fludarabine.

P W Johnson1, J Fearnley, P Domizio, J Goldin, K Nagendran, J Gawler, A Z Rohatiner, T A Lister.   

Abstract

Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine. These suggest that caution should be exercised in patients receiving fludarabine who develop neurological abnormalities, with prompt investigation and if necessary cessation of the drug.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7947105      PMCID： PMC2033535          DOI： 10.1038/bjc.1994.430

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  13 in total

1.  Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

Authors:  H S Hochster; K M Kim; M D Green; R B Mann; R S Neiman; M M Oken; P A Cassileth; P Stott; P Ritch; M J O'Connell
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

2.  Central nervous system toxicity with fludarabine.

Authors:  D E Merkel; N L Griffin; K Kagan-Hallet; D D Von Hoff
Journal:  Cancer Treat Rep       Date:  1986-12

3.  Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.

Authors:  D R Spriggs; E Stopa; R J Mayer; W Schoene; D W Kufe
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

4.  Central nervous system toxicity of fludarabine phosphate.

Authors:  H G Chun; B R Leyland-Jones; S M Caryk; D F Hoth
Journal:  Cancer Treat Rep       Date:  1986-10

5.  Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.

Authors:  J Suzuki; A Takaku
Journal:  Arch Neurol       Date:  1969-03

Review 6.  Phase I clinical trials with fludarabine phosphate.

Authors:  D D Von Hoff
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929

7.  A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.

Authors:  C A Puccio; A Mittelman; S M Lichtman; R T Silver; D R Budman; T Ahmed; E J Feldman; M Coleman; P M Arnold; Z A Arlin
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

8.  Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.

Authors:  M J Keating; S O'Brien; H Kantarjian; W Plunkett; E Estey; C Koller; M Beran; E J Freireich
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

9.  Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.

Authors:  R P Warrell; E Berman
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

10.  Fludarabine phosphate for the treatment of low grade lymphoid malignancy.

Authors:  J S Whelan; C L Davis; S Rule; M Ranson; O P Smith; A B Mehta; D Catovsky; A Z Rohatiner; T A Lister
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640
View more
  3 in total

Review 1.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 2.  Oral fludarabine.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Melissa Gabriel; Bianca A W Hoeben; Hilde Hylland Uhlving; Olga Zajac-Spychala; Anita Lawitschka; Dorine Bresters; Marianne Ifversen
Journal:  Front Pediatr       Date:  2021-12-23       Impact factor: 3.418
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.